Ro Launches AI-Powered Healthcare Research Lab
The telehealth firm's new unit will use artificial intelligence to study patient outcomes from its digital health platform.
Updated on Nov. 6, 2026 in Healthcare
Live Poll
Should insurers cover GLP-1 weight-loss drugs even when employers drop them?
Telehealth company Ro launched a healthcare research lab powered by artificial intelligence. The unit will analyze data generated through Ro's digital health platform, which has served millions of patients.
Why it matters
Some employers have dropped coverage of GLP-1 drugs due to rising medical costs, making real-world evidence on treatment outcomes a question of growing interest. Stronger data from the lab could help insurers assess the longer-term health and cost effects of covering these medications.
Ro's digital health platform has served millions of patients, the basis for the data its new AI research unit will analyze. The source does not provide a comparator figure, and the lab's first findings and the outcome of Ro's partnership talks with drug manufacturers remain unannounced.
The players
Ro
Ro is a telehealth company that offers cash-pay access to GLP-1 medications along with sexual health, hair loss, and skincare treatments.
Amgen
Amgen is a major biotechnology company that develops and markets prescription medicines, including treatments in the obesity space.
The details
Ro will use artificial intelligence to analyze data generated through its digital health platform, which also sells cash-pay access to Eli Lilly's Zepbound and Novo Nordisk's Wegovy through the manufacturers' direct pharmacies. The company is currently in talks with drug manufacturers about partnering with its research unit, and earlier this year it entered a research collaboration with Amgen to study access to obesity treatments.
Timeline
November 6, 2026: Ro announces the launch of its healthcare research lab.
This year (2026): Ro enters a research collaboration with Amgen on access to obesity treatments.
Market Landscape
Ro's cash-pay sales of Zepbound and Wegovy place it within the direct-to-consumer channel that manufacturers have expanded for GLP-1 drugs as employers have pulled back coverage. The research lab extends that position by turning platform patient data into evidence that drugmakers and insurers could weigh.
Patients weighing cash-pay access to GLP-1 drugs through telehealth platforms may see more evidence on outcomes as the lab's data develops. Employer coverage decisions on these medications remain a cost factor for workers whose plans have dropped them.
The takeaway
Real-world patient data is becoming a larger factor in how insurers and drugmakers evaluate expensive treatments. Readers tracking GLP-1 costs should watch whether Ro's research partnerships produce published findings.
Further reading
Explore more United States healthcare coverage on how drug access and insurance costs are shifting.
Live Poll
Should insurers cover GLP-1 weight-loss drugs even when employers drop them?
